Onco-Innovations (STU:W1H) Total Operating Expense: €6.74 Mil (TTM As of Apr. 2026)

Author: Vera Yuan Vera Yuan
Vera Yuan
Vera Yuan
Director of Data and Quant Analytics at GuruFocus
Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Reviewed by: Charlie Tian Charlie Tian
Charlie Tian
Charlie Tian
Founder & CEO of GuruFocus
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.

STU:W1H Onco-Innovations Ltd STU:W1H
12 GF Score
Price €0.33
! 2 Warning Signs
View Full Analysis

What is Onco-Innovations Total Operating Expense?

Onco-Innovations STU:W1H -2.79% 12 Total Operating Expense is €6.74 Mil as of Apr. 2026. GuruFocus rates STU:W1H with a GF Score™ of 12/100. The stock has 2 warning signs investors should review.

Onco-Innovations's Total Operating Expense for the three months ended in Apr. 2026 was €0.93 Mil. Onco-Innovations's Total Operating Expense for the trailing twelve months (TTM) ended in Apr. 2026 was €6.74 Mil.

Onco-Innovations Total Operating Expense Related Terms

Onco-Innovations Total Operating Expense Historical Data

* Premium members only.

The historical data trend for Onco-Innovations's Total Operating Expense can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Onco-Innovations Total Operating Expense Chart

Onco-Innovations Annual Data
Trend Apr23 Apr24 Apr25 Apr26
Total Operating Expense
0.00 0.18 3.01 6.77

Onco-Innovations Quarterly Data
Apr23 Apr24 Jul24 Oct24 Jan25 Apr25 Jul25 Oct25 Jan26 Apr26
Total Operating Expense Get a 7-Day Free Trial Premium Member Only Premium Member Only 1.27 1.67 2.26 1.88 0.93
STU:W1H
12GF Score
Onco-Innovations Ltd STU:W1H
Total Operating Expense is just one metric. See GF Score™, valuation, warning signs, and more.
View Full Analysis

Onco-Innovations Total Operating Expense Calculation

Total Operating Expense is the primary recurring expense associated with central operations that are incurred in order to generate sales.


Total Operating Expense for the trailing twelve months (TTM) ended in Apr. 2026 adds up the quarterly data reported by the company within the most recent 12 months, which was €6.74 Mil.

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

What does a Total Operating Expense of €6.74 Mil mean?
Onco-Innovations (STU:W1H) has a Total Operating Expense of €6.74 Mil as of Apr. 2026. Total operating expense is the primary recurring expense associated with central operations. View historical data on Onco-Innovations and its competitors.
Is Onco-Innovations' Total Operating Expense too high?
Onco-Innovations' current Total Operating Expense is €6.74 Mil. Overall, Onco-Innovations has a GF Score™ of 12/100, reflecting its overall financial health beyond just this single metric.
How does Onco-Innovations' Total Operating Expense compare to VRTX and REGN?
Onco-Innovations' Total Operating Expense of €6.74 Mil can be compared against companies in the Biotechnology industry. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Total Operating Expense for a Biotechnology company?
A good Total Operating Expense depends on the Biotechnology industry context. However, Total Operating Expense should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Total Operating Expense mean?
A high Total Operating Expense can signal that a stock is expensive relative to its fundamentals. Total operating expense is the primary recurring expense associated with central operations. View historical data on Onco-Innovations and its competitors. Onco-Innovations's current Total Operating Expense is €6.74 Mil. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Onco-Innovations stock overvalued right now?
Onco-Innovations (STU:W1H) has a current Total Operating Expense of €6.74 Mil. The current Total Operating Expense is €6.74 Mil. Onco-Innovations' overall GF Score™ is 12/100 with 2 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Total Operating Expense calculated?
Total Operating Expense is calculated from a company's financial statements. For Onco-Innovations (STU:W1H), the current Total Operating Expense is €6.74 Mil as of Apr. 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.

Onco-Innovations Business Description

Other Exchanges ONCO:Canada
Address 7th Street South West, Suite 1039, Calgary, AB, CAN, T2R 1A5
Onco-Innovations Ltd is a pre-clinical stage biotechnology company working on developing drug candidates that can increase the effectiveness of current cancer treatments.
12GF Score

Get the complete analysis for STU:W1H

Total Operating Expense is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.

€0.33
Price